/C O R R E C T I O N -- ThyroSeq/

In the news release, American Cancer Society® Published Performance Results Of ThyroSeq® V3, issued 25-Jan-2018 by ThyroSeq over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "ThyroSeq announced that the results of the comprehensive analytic validation study of ThyroSeq V3 have been published by cancer.org, the publishing platform of The American Cancer Society" rather than "Sonic Healthcare USA and University of Pittsburgh Medical Center are pleased to announce that the results of the comprehensive analytic validation study of ThyroSeq V3 have been published by cancer.org, the publishing platform of The American Cancer Society" as originally issued inadvertently. The complete, corrected release follows:

AUSTIN, Texas, Jan. 25, 2018 /PRNewswire/ -- ThyroSeq announced that the results of the comprehensive analytic validation study of ThyroSeq V3 have been published by cancer.org, the publishing platform of The American Cancer Society. The published performance results provide extensive analytical and also clinical validation of the performance of ThyroSeq V3 in thyroid nodules with indeterminate cytology. It demonstrated that the established new version 3 of ThyroSeq provides robust analytical performance as a diagnostic tool for all types of thyroid nodules, which is required for its use for patient care.

Highlights of the published study include:

• ThyroSeq V3 provides sensitive detection of five different classes of genetic alterations, making it the most comprehensive test for thyroid nodules and cancer.
• ThyroSeq V3 allows accurate diagnosis of all types of Hurthle cell cancer in thyroid fine-needle aspiration (FNA) samples.
• ThyroSeq V3 offers high analytical accuracy in small samples, which is particularly important for thyroid FNA samples, and provides reproducible test results under variable sample stress conditions, which assures its high-level performance in various clinical settings.

"The peer-reviewed appraisal of the analytical and early clinical validation of the test is an important step in accelerating its clinical use. It confirms the robust performance of the test in the laboratory and provides basis for comprehensive clinical validation of the test in a prospective multi-center study the results of which are currently in preparation for publication," said Yuri Nikiforov, M.D., Ph.D., Professor of Pathology at University of Pittsburgh Medical Center, and principle of ThyroSeq.

According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades. Most physicians have traditionally recommended thyroid surgery where thyroid nodule biopsy results are indeterminate, not clearly benign or malignant following traditional cytopathology review; however, 70%-80% of these surgical outcomes are ultimately benign. Genetic testing using ThyroSeq V3 can lead to avoiding surgery for more than 60% of patients with indeterminate thyroid nodules.

Source: Nikiforova, M. N., Mercurio, S., Wald, A. I., Barbi de Moura, M., Callenberg, K., Santana-Santos, L., Gooding, W. E., Yip, L., Ferris, R. L. and Nikiforov, Y. E. (2018), Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer. doi: 10.1002/cncr.31245

Study has published in The American Cancer Society's Journal, Cancer:http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31245/full

About ThyroSeq 
ThyroSeq is an innovative proprietary test offered through a partnership between UPMC and Sonic Healthcare USA, which through 10 years of continuous refinement incorporates all major scientific discoveries and utilizes advanced technology to provide the most accurate diagnosis of whether malignant disease is present in thyroid nodules. For more information, visit www.ThyroSeq.com.  

About Sonic Healthcare USA
Sonic Healthcare USA serves as the umbrella organization overseeing Sonic Healthcare Ltd's operations in the United States.  Similar to Sonic Healthcare Ltd's federation structure in Australia, New Zealand and throughout Europe, each laboratory in the United States is an independent entity with its own management and medical team that are united by Sonic Healthcare's common values. In the federation structure, laboratories operate autonomously, responding to the local needs of the medical communities they serve, tailoring their offerings to meet the demands of each community's physicians. By sharing and comparing information among federation members, best practices can be developed and adopted by federation members.  For additional information, please visit www.SonicHealthcareUSA.com.

MEDIA CONTACT 
Jeanine Wilson
Phone: 917-841-8565
Email: thyroseq@wmediagroup.com

View original content with multimedia:http://www.prnewswire.com/news-releases/american-cancer-society-published-performance-results-of-thyroseq-v3-300588430.html

SOURCE ThyroSeq